At least for gynecological cancer, CrkL was shown to be a regulator of alternative splicing of several genes involved in cancer progression, although it was not clear that CCR7 underwent alternative splicing that could be related to cancer progression [306] Results for CrkL are not consistent since, in lung cancer, high CCR7 mRNA was co-expressed with CrkL and c-ABL expression, which in this case led to better prognosis [219]. This evidence concerns the gene CCR7 and female reproductive organ cancer.